Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glasdegib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glasdegib SCHEMBL29362720 | 1.00 | EPHX1 (0.44) | EPHX1USP30NPC1RAB9APOLB | |
| Glasdegib SCHEMBL22104131 | 0.99 | EPHX1 (0.45) | EPHX1USP30NPC1RAB9APOLB | |
| Glasdegib SCHEMBL27100349 | 0.99 | EPHX1 (0.45) | EPHX1USP30NPC1RAB9APOLB | |
| Glasdegib SCHEMBL18184932 | 0.99 | EPHX1 (0.45) | EPHX1USP30NPC1RAB9APOLB | |
| Glasdegib SCHEMBL2068480 | 0.99 | EPHX1 (0.45) | EPHX1USP30NPC1RAB9APOLB | |
| Glasdegib SCHEMBL24503991 | 0.99 | EPHX1 (0.45) | EPHX1USP30NPC1RAB9APOLB | |
| Glasdegib SCHEMBL29359708 | 0.99 | EPHX1 (0.45) | EPHX1USP30NPC1RAB9APOLB | |
| Glasdegib SCHEMBL18171549 | 0.94 | USP30 (0.41) | EPHX1USP30NPC1RAB9APOLB | |
| Glasdegib SCHEMBL29359798 | 0.94 | USP30 (0.41) | EPHX1USP30NPC1RAB9APOLB | |
| Glasdegib SCHEMBL18171548 | 0.94 | USP30 (0.41) | EPHX1USP30NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023017541-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYL PIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA MALEATE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-02-16 | — | — | WO | disclosed |
| EP-2170860-B9 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2170860-B1 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8431597-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2012-06-21 | — | — | US | disclosed |
| US-8148401-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | BOD1L1, H1-3, BRIX1 | EPHX1 4079/4885USP30 4188/4885NPC1 2444/4885 |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | BOD1L1, H1-3, BRIX1 | EPHX1 4079/4885USP30 4188/4885NPC1 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.